Entropy Neurodynamics Limited · ASX:ENP
Entropy Neurodynamics — Investor Presentation (December 2025)
18 slides from Entropy Neurodynamics's investor presentation, December 2025
Slide 1: Advancing Psychedelic Science for Disorders in Neuropsychiatry
Advancing Psychedelic Science for Disorders in Neuropsychiatry December 2025 This presentation has been authorised for release by the Board of Entropy Neurodynamics Limited ASX : ENP
Slide 2: Disclaimers
DISCLAIMERS The information contained in this presentation (the “Presentation”) has been prepared by Tryp Therapeutics Inc. (“Tryp” or th e “Company”) and contains information pertaining to the business, operations and assets of the Company. The information containe d in this Presentation (a) is pro
Slide 3: Entropy Neurodynamics – The Best Kept Secret on the ASX
ENTROPY NEURODYNAMICS – THE BEST KEPT SECRET ON THE ASX Corporate Snapshot ASX code: ENP Top 20 Holders Shares on issue: 1.560Bn Market capitalisation: AU$51.5m (at $0.032 per share) Cash at bank: AU$1.3m* (as at 30 Sept 2025) Shareholders (at 30 November 2025) Debt: Nil Dr. William James Garner (Co
Slide 4: Unparalleled Ability of Psilocin to Modulate Serotonin 5-HT2A
UNPARALLELED ABILITY OF PSILOCIN TO MODULATE SEROTONIN 5-HT2A Psilocin molecules activate the serotonin 5HT2A receptor due to structural similarity between Psilocin occupancy of 5-HT2A Receptors psilocin & serotonin. Madsen, M.K., Fisher, P.M., Burmester, D. et al. Psychedelic effects of psilocybin
Slide 5: Psilocybin (TRP-8802) Has Shown Success in Neuropsychiatric Conditions
PSILOCYBIN (TRP-8802) HAS SHOWN SUCCESS IN 3 NEUROPSYCHIATRIC CONDITIONS Fibromyalgia Binge Eating Disorder Irritable Bowel Syndrome 05 ENTROPY NEURODYNAMICS: Advancing Psychedelic Science for Disorders in Neuropsychiatry
Slide 6: Design the Approach to Remove the Barriers to Therapy
DESIGN THE APPROACH TO REMOVE THE BARRIERS TO THERAPY TRP-8803 : A Precision approach in Neuropsychiatry IV-infused Psilocin Oral Psilocybin * Short treatment duration of 1-2 hours ~8-10 hours Quick onset of psychedelic state (~15 minutes) 1-2 hours Precision targeting of drug blood levels in patien
Slide 7: The Clinical Drawbacks of Oral Psilocybin Treatment
THE CLINICAL DRAWBACKS OF ORAL PSILOCYBIN TREATMENT Blood level of Psilocin after taking a standard 25mg capsule of Psilocybin ISSUE 3 - IMPRECISION Time to reach a ISSUE 2 – SIDE EFFECTS therapeutic psilocin level Attempts to dose in any patient is 1 – 3 escalate to lift patients hours with highly
Slide 8: Results Phase I TRP-8803 Clinical Safety and Dose Ranging Study
RESULTS PHASE I TRP-8803 CLINICAL SAFETY AND DOSE RANGING STUDY TRP-8803 achieves consistent blood levels • Established Safety of TRP-8803 IV-infusion within a target therapeutic zone across diverse cohorts • Confirmed achievement of target blood levels of psilocin within the Therapeutic Zone • Conf
Slide 9: Has Big Pharma Finally Seen the Psy-Light?
HAS BIG PHARMA FINALLY SEEN THE PSY-LIGHT? US$1,200M transaction for a pharmaceutical small molecule, bretisilocin (at Phase 2a) is a very potent signal from the company considered to be the leading acquirer of new products in new therapeutic areas. 2 hour, IV-bolus – bretisilocin in a rapid acting
Slide 10: First Patients Dosed in World-First Binge Eating Disorder Study
FIRST OF 12 PATIENTS DOSED IN WORLD-FIRST BINGE EATING DISORDER STUDY 10 ENTROPY NEURODYNAMICS: Advancing Psychedelic Science for Disorders in Neuropsychiatry
Slide 11: How Will TRP-8803 & Entropy Transform Neuropsychiatry?
HOW WILL TRP-8803 & ENTROPY TRANSFORM NEUROPSYCHIATRY? Entropy is a measurable, dynamic Neural Biomarker of a patient’s mental health status Patients suffering from neuropsychiatric conditions have a lower level of brain entropy than those without these conditions Psilocin is a highly efficacious 5-
Slide 12: What Happens to a Patient Undergoing IV-Infusion of TRP-8803?
WHAT HAPPENS TO A PATIENT UNDERGOING IV-INFUSION OF TRP-8803? 12 ENTROPY NEURODYNAMICS: Advancing Psychedelic Science for Disorders in Neuropsychiatry
Slide 13: New Neuropsychiatric Conditions – FM, IBS & BED Are Globally Equivalent to Depression & Anxiety Market
NEW NEUROPSYCHIATRIC CONDITIONS – FM, IBS & BED ARE GLOBALLY EQUIVALENT TO THE SIZE OF THE TOTAL DEPRESSION & ANXIETY MARKET 13 ENTROPY NEURODYNAMICS: Advancing Psychedelic Science for Disorders in Neuropsychiatry
Slide 14: Years Developing & Refining the Infusion Chair Placement Model
15 YEARS DEVELOPING & REFINING THE INFUSION CHAIR PLACEMENT MODEL USA – Remicade IV-infusion chair placement in Gastroenterological offices Philippines & Vietnam – Infusion chair placement across Oncology Hospital networks Highly profitable model for specialists to infuse therapies “in-office” • Con
Slide 15: Entropy Neurodynamics' Business Model Involves Infusion E-POD
ENTROPY NEURODYNAMICS’ BUSINESS MODEL INVOLVES INFUSION “E-POD” PLACEMENT WITHIN PSYCHIATRY SURGERIES & CLINICS ENTROPY LOUNGE ENTROPY VAULT Graphical representation of Entropy Pods (E-POD) in “Lounge” (TRI-POD) and “Vault” (PENTA-POD) formations The placement of a single e-pod plus associated infus
Slide 16: Global Intellectual Property Portfolio
GLOBAL INTELLECTUAL PROPERTY PORTFOLIO Patent applications and trade secrets based on novel methods for manufacturing, formulation, dosing and treatment of specific disease indications have been filed for all major global pharmaceutical markets ￭ Provisional patent filed in March 2021 (US 63/161,070
Slide 17: Historical Milestones & Pending Catalysts
HISTORICAL MILESTONES & PENDING CATALYSTS* Milestone Timing Status Completion of Tryp Therapeutics Inc. acquisition and $6.5m capital raise H1 CY24 Recommencement of trading of on ASX H1 CY24 Appointments to strengthen Scientific Advisory Board H1 CY24 Start of TRP-8803 Phase 1 trial (Australia) H1
Slide 18: Contact
CONTACT Jason Carroll Henry Jordan Chief Executive Officer Six Degrees Investor Relations jcarroll@entropyneurodynamics.com henry.jordan@sdir.com.au Website: Socials: www.entropyneurodynamics.com X (Twitter) @tryptherapeutic
Entropy Neurodynamics — Investor Presentation (December 2025) on 6ix